Water soluble inhibitors of topoisomerase I: Quaternary salt derivatives of camptothecin

Journal of Medicinal Chemistry

Volumn 39, Issue 3, 1996, Pages 713-719

  Lackey, Karen ^a   Sternbach, Daniel D ^a   Croom, Dallas K ^a   Emerson, David L ^a   Evans, Michael G ^a   Leitner, Peter L ^a   Luzzio, Michael J ^a   McIntyre, Gordon ^a   Vuong, Alain ^a   Yates, Julie ^a   Besterman, Jeffrey M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; COLON CANCER; DNA REPLICATION; DNA STRAND BREAKAGE; DNA TRANSCRIPTION; ENZYME ACTIVATION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MULTIDRUG RESISTANCE; NUCLEAR MAGNETIC RESONANCE; OVARY ADENOCARCINOMA; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLONIC NEOPLASMS; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; MICE, NUDE; OVARIAN NEOPLASMS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; WATER;

EID: 13344262703     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950507y     Document Type: Article

References (33)

1. Osheroff, N. Biochemical Basis for the Interactions of Type I and Type II Topoisomerases with DNA. Pharmacol. Ther. 1989, 41, 223-241.
2. Lui, L. F.; Wang, J. C. Biochemistry of DNA Topoisomerases and Their Poisons. In DNA Topoisomerases in Cancer; Potmesil, M., Kohn, K. W., Eds.; Oxford University Press: New York, 1991; Chapter 2, pp 13-22 and references cited therein.
3. Caserta, M.; Amadei, A.; Camilloni, G.; Di Mauro, E. Regulation of the function of Eukaryotic DNA Topoisomerase I: Analysis of the Binding Step and of the Catalytic Constants of Topoisomerization as a Function of DNA Topology. Biochemistry 1990, 29, 8152-8157.
4. Giovanella, B. P.; Stehlin, J. S.; Wall, M. E.; Wani, M.; Nicholas, A. W.; Liu, L. F.; Silber, R.; Potmesil, M. DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenografts. Science 1989, 246, 1046-1048.
5. Husain, I.; Mohler, J. L.; Siegler, H. F.; Besterman, J. M. Elevation of Topoisomerase I Messenger RNA, Protein, and Catalytic Activity in Human Tumors: Demonstration of Tumor-Type Specificity and Implications for Cancer CHemotherapy. Cancer Res. 1994, 54, 539-546.
6. Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K H.; McPhail, A. T.; Sim, G. A. Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966, 88, 3888-3890.
7. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin Induces Protein-Linked DNA Breaks via Mammalian DNA Topoisomerase I. J. Biol. Chem. 1985, 260, 14873-14878.
8. Hertzberg, R. P.; Caranfa, M. J.; Kingsbury, W. D.; Smith, B.; Johnson, R. K.; Hecht, S. M. In DNA Topoisomerases in Cancer; Potmesil, M., Kohn, K. W., Eds.; Oxford University Press: New York, 1991; pp 103-120.
9. Hsiang, Y. H.; Lihou, M. G.; Liu, L. F. Arrest of Replication Forks by Drug-Stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin. Cancer Res. 1989, 49, 5077-5082.
10. Hertzberg, R. P.; Caranfa, M. J.; Holden, K. G.; Jakas, D. R.; Gallager, G.; Mattern, M. R.; Mong, S. M.; Bartus, J. O.; Johnson, R. K.; Kingsbury, W. D. Modification of the Hydroxylactone Ring of Camptothecin: Inhibition of Mammalian Topoisomerase I and Biological Activity. J. Med. Chem. 1989, 32 (3), 715-720.
11. Gottlieb, J. A.; Guarino, A. M.; Call, J. B.; Oliverio, V. T.; Block, J. B. Preliminary Pharmacologic and Clinical Evaluation of Camptothecin Sodium (NSC-1000880). Cancer Chemother. Rep. 1970, 54, 461-470.
12. Muggia, F. M.; Creaven, P. J.; Hansen, H. H.; Cohen, M, H.; Selawry, O. S. Phase I Clinical Trial of Weekly and Daily Treatment with Camptothecin. Cancer Chemother. Rep. 1972, 56, 515-521.
13. Wani, M. C.; Ronman, P. E.; Lindley, J. T.; Wall, M. E. Plant Antitumor Agents. 18. Synthesis and Biological Activity of Camptothecin Analogs. J. Med. Chem. 1980, 23, 554-560.
14. Fassberg, J.; Stella, V J. A Kinetic and Mechanistic Study of the Hydrolysis of Camptothecin and Some Analogs. J. Pharm. Sci. 1992, 81, 676-684.
15. Kingsbury, W. D.; Boehm, J. C.; Jakas, D. R.; Holden, K. G.; Hecht, S. M.; Gallagher, G.; Caranfa, M. J.; McCabe, F. L.; Faucette, L. F.; Johnson, R. K.; Hertzberg, R. P. Synthesis of Water-Soluble (Aminoalkyl)camptothecin Analogs: Inhibition of Topoisomerase I and Antitumor Activity. J. Med. Chem. 1991, 34, 98-107.
16. Burris, H. A.; Awada, A.; Kuhn, J. G.; Eckardt, J. R.; Cobb, P. W.; Rinaldi, D. A.; Fields, S.; Smith, L.; Von Hoff, D. D. Phase I and Pharmacokinetic Studies of Topotecan Administered as a 72- or 120-H Continuous Infusion. Anti-Cancer Drugs 1994, 5, 394-402.
17. Rowinsky, E. K.; Grochow, L. B.; Hendricks, C. B.; Ettinger, D. S.; Forastiere, A. A.; Hurowitz, L. A.; Mcguire, W P.; Sartorius, S. E.; Lubejko, B. G.; Kaufman, S. H.; Donehower, R. C. Phase I and Pharmacological Study of Topotecan. A Novel Topoisomerase I Inhibitor. J. Clin. Oncol. 1992, 10, 647-656.
18. Fukuoka, M.; Niitani, H.; Susuki, A.; Motomiya, M ; Hasegawa, K.; Nishiwaki, Y ; Kuriyama, T.; Airyoshi, Y.; Negoro, S.; Masuda, N.; Nakajima, S.; Taguchi, T. Phase II Study of CPT-11, a New Derivative of Camptothecin, for Previously Untreated Non-Small-Cell Lung Cancer. J. Clin. Oncol. 1992, 10, 16-20.
19. Emerson, D. L.; Besterman, J. M.; Brown, H. R.; Evans, M. G.; Leitner, P. P.; Luzzio, M. J.; Shaffer, J. E.; Sternbach, D. D.; Uehling, D. E.; Vuong, A. In Vivo Antitumor Activity of two New Seven-Substituted Water Soluble Camptothecin Analogs. Cancer Res. 1995, 55, 603-609.
20. Luzzio, M. J.; Besterman, J. M.; Emerson, D. L.; Evans, M. G.; Lackey, K.; Leitner, P. L.; McIntyre, G.; Morton, B.; Myers, P. L.; Peel, M.; Sisco, J. M.; Sternbach, D. D.; Tong, W.-Q ; Truesdale, A.; Uehling, D. E.; Vuong, A.; Yates, J. Synthesis and Antitumor Activity of Novel Water Soluble Derivatives of Camptothecin as Specific Inhibitors of Topoisomerase I. J. Med. Chem 1995, 38, 395-401.
21. Rose, K. M. DNA Topoisomerases as Targets for Chemotherapy. FASEBJ. 1988, 2474-2478. D'Arpa, P.; Liu, L. F. Topo-isomerase-Targeting Antitumor Drugs. Biochim Biophys. Acta 1989, 989, 163-177. Su, T. L.; Chou, T. C.; Watanabe, K. A. DNA Topoisomerase Targeted Anticancer Agents: New Trends and Developments. In DNA Topoisomerases in Cancer; Potmesil, M., Kohn, K. W., Eds.; Oxford University Press: New York, 1991.
22. Rose, K. M. DNA Topoisomerases as Targets for Chemotherapy. FASEBJ. 1988, 2474-2478. D'Arpa, P.; Liu, L. F. Topo-isomerase-Targeting Antitumor Drugs. Biochim Biophys. Acta 1989, 989, 163-177. Su, T. L.; Chou, T. C.; Watanabe, K. A. DNA Topoisomerase Targeted Anticancer Agents: New Trends and Developments. In DNA Topoisomerases in Cancer; Potmesil, M., Kohn, K. W., Eds.; Oxford University Press: New York, 1991.
23. Rose, K. M. DNA Topoisomerases as Targets for Chemotherapy. FASEBJ. 1988, 2474-2478. D'Arpa, P.; Liu, L. F. Topo-isomerase-Targeting Antitumor Drugs. Biochim Biophys. Acta 1989, 989, 163-177. Su, T. L.; Chou, T. C.; Watanabe, K. A. DNA Topoisomerase Targeted Anticancer Agents: New Trends and Developments. In DNA Topoisomerases in Cancer; Potmesil, M., Kohn, K. W., Eds.; Oxford University Press: New York, 1991.
24. Wall, M. E.; Wani, M. C.; Nicholas, A. W.; Manikumar, G.; Tele, C. A.; Moore, L.; Truesdale, A.; Leitner, P.; Besterman, J. M. Plant Antitumor Agents. 30. Synthesis and Structure Activity of Novel Camptothecin Analogs. J. Med. Chem. 1993, 36, 2689-2700.
25. Sawada, S.; Matsuoka, S.; Nokata, H.; Furuta, T.; Yokokura, T.; Miyasaka, T. Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: A-Ring Modified and 7,10-Disubstituted Camptothecins. Chem. Pharm. Bull. 1991, 39, 3183-3188.
26. Glaxo Research Institute Synthetic Organic Chemistry Department graciously supplied the optically pure tricyclic keto lactone 8. Wani, M. C.; Nicholas, A. W.; Wall, M. E. Plant Antitumor Agents. 28. Resolution of a Key Tricyclic Synthon, 5′(RS)-1,5-Dioxo-5′-hydroxy-2′H,5′H,6′H-6′- oxopyrano[3',4'-fl.A.6,8-tetrahy-droindolizine: Total Synthesis and Antitumor Activity of 20-(S)- and 20(R)-Caniptothecin. J. Med. Chem. 1987, 30, 2317-2319. Wani, M. C.; Campbell, H. F.; Brine, G. A.; Kepler, J. A.; Wall, M. E.; Levine, S. G. Plant Antitumor Agents. IX. Total Synthesis of dl-Camptothecin. J. Am. Chem. Soc. 1972, 94, 3631-3632.
27. Glaxo Research Institute Synthetic Organic Chemistry Department graciously supplied the optically pure tricyclic keto lactone 8. Wani, M. C.; Nicholas, A. W.; Wall, M. E. Plant Antitumor Agents. 28. Resolution of a Key Tricyclic Synthon, 5′(RS)-1,5-Dioxo-5′-hydroxy-2′H,5′H,6′H-6′- oxopyrano[3',4'-fl.A.6,8-tetrahy-droindolizine: Total Synthesis and Antitumor Activity of 20-(S)- and 20(R)-Caniptothecin. J. Med. Chem. 1987, 30, 2317-2319. Wani, M. C.; Campbell, H. F.; Brine, G. A.; Kepler, J. A.; Wall, M. E.; Levine, S. G. Plant Antitumor Agents. IX. Total Synthesis of dl-Camptothecin. J. Am. Chem. Soc. 1972, 94, 3631-3632.
28. The pH was corrected for taking the measurement in deuterium oxide according to the following formula: pD = pH + 0.40.
29. Topotecan was used for comparison with our compounds because it is an active topoisomerase I inhibitor and it is active in vivo.
30. Liu, L. F.; Rowe, T. C.; Tewey, K. M.; Chen, G. L. Cleavage of DNA by Mammalian DNA Topoisomerase II. J. Biol. Chem. 1983, 258, 15365-15370.
31. Tewey, K. M.; Chen, G. L.; Nelson, E. M.; Liu, L. F. Intercalative Antitumor Drugs Interfere with the Breakage-reunion Reaction of Mammalian DNA Topoisomerase II. J. Biol. Chem. 1984, 259, 9182-9187.
32. Strausfeld, U.; Richter, A. Purification of DNA Topoisomerase I and II from Eukaryotic Cells. Prep. Biochem. 1989, 19, 37-48.
33. Plumb, J. A.; Milroy, R.; Kaye, S. B. Effects of the pH Dependence of 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenylltetrazolium Bromide-formazan Absorption on Chemosensitivity Determined by a Novel Tetrazolium-Based Assay. Cancer Res. 1989, 49, 4435-4440.